Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Low-Dose Psilocybin on Pain in Fibromyalgia and Healthy Volunteers
2021-002909-10Phase 2Active
- Sponsor
- Maastricht University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of psilocybin in fibromyalgia (FM) (2 arms), sponsored by Maastricht University. Primary endpoints: Pain tolerance and Painfulness ratings. Started Dec 2021; status: active.
02
Drugs
psilocybin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on 2021-002909-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002909-10.